Eli Lilly and Company / Hanmi Pharmaceutical Co., Ltd. (HM71224 program)

Rheumatoid Arthritis and Other Autoimmune Diseases

Disease Overview

Rheumatoid arthritis is a chronic systemic autoimmune disease in which immune dysregulation drives synovial inflammation, joint destruction, and extra-articular complications. Despite TNF inhibitors transforming care, roughly a third of patients fail or lose response to first biologic therapy, and oral targeted agents had been limited at deal time to JAK inhibitors with their own safety trade-offs.

Competitive Landscape

At the time of the 2015 Lilly-Hanmi deal, the RA market was anchored by TNF inhibitors AbbVie's Humira (adalimumab), Amgen's Enbrel (etanercept), and J&J's Remicade (infliximab), with biologics receiving roughly 53% of US treated patients. The first-in-class oral JAK inhibitor Pfizer's Xeljanz (tofacitinib, approved 2012) was emerging as the only oral targeted alternative, generating $1.2B in 9-month 2018 sales, with AbbVie's Rinvoq and Lilly's own Olumiant (baricitinib) advancing. Hanmi's HM71224 (poseltinib) was positioned as a differentiated oral BTK inhibitor that, unlike JAKs, would target B-cell and monocyte signaling without broad cytokine suppression. The strategy collapsed in February 2018 when Lilly halted the RAjuvenate Phase 2 trial at interim analysis after the placebo-vs-active arm difference was 'not sufficient enough to support continuation'. Lilly returned rights in January 2019. The result reinforced that BTK inhibition - established in B-cell malignancies via Imbruvica and Calquence - has struggled to translate to autoimmune indications outside chronic spontaneous urticaria. Hanmi later repositioned poseltinib for relapsed/refractory DLBCL.